
Risk factors associated with diabetic ketoacidosis typically do not change. Preventing DKA should focus on identification of those most at risk and educating them good self-care to avoid incidents.

Risk factors associated with diabetic ketoacidosis typically do not change. Preventing DKA should focus on identification of those most at risk and educating them good self-care to avoid incidents.

Coverage from the 64th Scientific Sessions of the American College of Cardiology.

Coverage from the 64th Scientific Sessions of the American College of Cardiology.

The findings in Diabetes Care served as early confirmation of what some had feared: a bifurcated Medicaid system will lead to an American of haves and have-nots in healthcare.

An evidence review supports a proposed USPSTF recommendation to update how the healthcare system screens for prediabetes.

Major professional and advocacy groups back legislation to create access to the National Diabetes Prevention Program.

With the right support, community providers can offer an effective approach to promoting population health and preventing chronic disease.

The CDC's director of the Division of Diabetes Translation discusses the scientific evidence that supports the need for both lifestyle interventions and population-level efforts to combat type 2 diabetes in the United States.

Studies offer insights for patients with atrial fibrillation and type 2 diabetes mellitus, with more results to come.

The FDA said it had received 20 reports in the 15 months since the first of the SGLT2 inhibitor class was approved, and had continued to receive reports since that time. All drugs in the class were included in the safety communication.

What one type 1 diabetic has learned from living and coping with diabetes for 42 years.

The study, conducted by the Global eHealth Unit at the Imperial College London, has found that the majority of insulin dosing apps are unreliable and put patients at risk of getting incorrect doses of insulin. Does this demand an FDA oversight of the apps?

The prices for new hepatitis C and cancer treatments are driving the cost of prescription drugs to new highs for more Americans, according to a new report, which found that 9 of 10 patients with drug costs of $50,000 or more used specialty drugs.

A very small segment of the Medicaid-only population-those who are not also eligible for Medicare-accounted for almost half of expenditures for all Medicaid-only enrollees from 2009 to 2011, according to a new report from the Government Accountability Office.

February's report from the Dietary Guidelines Advisory Committee called for an emphasis on plant-based diets and less red or processed meat. Protests from the meat industry followed, and the comment period was extended until Friday.

The average per capita spending difference between people with and without diabetes was $10,310 from 2009 to 2013, according to a new report from the Health Care Cost Institute.

Amarin's action has initiated a debate on whether the FDA's authority over ensuring the safety and efficacy is being side-stepped.

Behavior, including adherence behavior, are the keys to improving outcome in a variety of diseases. We must rethink our adherence strategy by using Intelligent Engagement to control the plecosystem of adherence technologies.

My mission: getting approval for a supply of blood glucose testing strips my endocrinologist recommends, so I can manage my diabetes and maintain my great quality of life.


Lancet editors criticized the "unacceptably slow" global response to rising rates of childhood obesity.

Among other topics, panelists discussed the connection between mental health and diabetes, and the need to treat these conditions together.

FDA approves a key combination therapy for type 2 diabetes mellitus, a device to help patients battle obesity, and another indication for Lucentis.

The Affordable Care Act provided funds for 10 states to experiment with incentive programs in Medicaid. Researchers hope to learn what steps will motivate beneficiaries to take steps to improve their health.

The pharmaceutical industry has learnt its lesson from the pushback that Gilead faced over the price of its hepatitis C drug, Sovaldi. The lack of a price discussion prior to the introduction of the regimen washed-out the excitement over a "cure" for the disease.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
